TLTFF (Theralase Technologies) LT-Debt-to-Total-Asset : 0.06 (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Theralase Technologies LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Theralase Technologies's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.06.

Theralase Technologies's long-term debt to total assets ratio declined from Dec. 2023 (0.09) to Dec. 2024 (0.06). It may suggest that Theralase Technologies is progressively becoming less dependent on debt to grow their business.

Theralase Technologies LT-Debt-to-Total-Asset Historical Data

The historical data trend for Theralase Technologies's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies LT-Debt-to-Total-Asset Chart

Theralase Technologies Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.09

0.06

Theralase Technologies Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.09	0.08	0.07	0.07	0.06

Theralase Technologies LT-Debt-to-Total-Asset Calculation

Theralase Technologies's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	0.136	/	2.279
	=	0.06

Theralase Technologies's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	0.136	/	2.279
	=	0.06

Theralase Technologies (OTCPK:TLTFF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Theralase Technologies LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Theralase Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (OTCPK:TLTFF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

TTX:Germany TTX:Germany TLT:Canada

Address

41 Hollinger Road, Toronto, ON, CAN, M4B 3G4

Website

https://www.theralase.com

Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.